Lars Damstrup

Lars Damstrup is an experienced medical professional currently serving as Chief Medical Officer at Scandion Oncology since September 2023. Previously, Lars held the position of Medical Doctor at LGD Medical Consultancy from July 2022 to September 2023, and served as Medicinsk direktør at Debiopharm International SA from April 2019 to July 2022. Lars has a strong background in oncology, having worked as Senior Medical Director at Symphogen A/S and as Senior Medical Director for Oncology at the Healthcare Business of Merck, where significant contributions included leading pivotal studies for DNA-PK inhibitors and Belinostat, culminating in FDA approval for certain indications. Lars's medical expertise is complemented by advanced education, including an MD and a PhD in Receptor Biology from Københavns Universitet, as well as specialized training in Oncology and business management courses.